3-[4-(methylamino)phenyl]-4H-1,2,4-oxadiazol-5-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[4-(methylamino)phenyl]-4H-1,2,4-oxadiazol-5-one
• 化学式: C₉H₉N₃O₂
• 分子量: 191.19
• InChiKey: IZYYWIOPUASWQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  62.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Process for the Synthesis of Dabigatran and Its Intermediates
  申请人：BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.

  公开号：US20150246900A1

  公开（公告）日：2015-09-03

  The present invention describes an improved process for the preparation of Dabigatran Etexilate (Formula-I), a pharmaceutically acceptable salt for the treatment of thromboses, cardiovascular diseases etc. and intermediates involved in the synthesis.

  本发明描述了一种改进的制备达比加群酯（Formula-I）的过程，该化合物是治疗血栓、心血管疾病等的药用盐，同时涉及合成中间体。
• Process for the Synthesis of Dabigatran Etexilate and Its Intermediates
  申请人：Biophore India Pharmaceuticals PVT. Ltd.

  公开号：US20170050948A1

  公开（公告）日：2017-02-23

  The present invention describes an improved process for the preparation of Dabigatran Etexilate (Formula-VII) or it's pharmaceutically acceptable salt for the treatment of thrombosis, cardiovascular diseases etc. and intermediates involved in the synthesis.
• US9533971B2
  申请人：——

  公开号：US9533971B2

  公开（公告）日：2017-01-03